There are currently 28 active clinical trials seeking participants for Interstitial Lung Disease research studies. The states with the highest number of trials for Interstitial Lung Disease participants are California, Texas, Florida and New York.
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
NCT06855329
Recruiting
This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis (PPF) classification and establish PPF incidence for key ILD subtypes. Additional exploratory objectives are to 1) Prospectively validate a novel PPF classifier and assess performance durability over... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/18/2025
Locations: University of Massachusetts Chan Medical School, Worcester, Massachusetts +12 locations
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: UAB Lung Health Center, Birmingham, Alabama +130 locations
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
NCT06325696
Recruiting
Background: Interstitial lung disease affects the tissues that aid the transfer of oxygen and carbon dioxide between the air and the bloodstream. The disease can cause fibrosis, a thickening and scarring of lung tissue. Fibrosis often continues getting worse, and most people with this disease die in 3 to 5 years. Objective: To test a study drug (hymecromone) in people with interstitial lung disease or lung fibrosis. Eligibility: People aged 18 years and older with interstitial lung disease... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/09/2025
Locations: NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina
Conditions: Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial
Register for Updates
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421
Recruiting
This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +21 locations
Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
FAPI PET for Lung Fibrosis
NCT05365802
Recruiting
This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease. The study will include patients with interstitial lung disease who have or will initiate a new ILD medication OR will undergo tissue biopsy or surgery of the lung. The study will include 30 p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Interstitial Lung Disease, Idiopathic Interstitial Pneumonias, Drug-Induced Pneumonitis, Hypersensitivity Pneumonitis, Radiation Pneumonitis, Pneumoconiosis, Pulmonary Fibrosis
Register for Updates
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Pulmonary Associates, Phoenix, Arizona +41 locations
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension
NCT03814317
Recruiting
This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/26/2025
Locations: University of Florida, Division of Pulmonary and Critical Care Medicine, Gainesville, Florida
Conditions: Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
A Study of Mosliciguat in PH-ILD
NCT06635850
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/11/2025
Locations: Arizona Pulmonary Specialists, Phoenix, Arizona +17 locations
Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Register for Updates
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
NCT06129240
Recruiting
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/30/2025
Locations: Arizona Pulmonary Specialists, Phoenix, Arizona +22 locations
Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
Collagen-targeted PET Imaging for Early Interstitial Lung Disease
NCT05417776
Recruiting
The goal of this study is to investigate the ability of \[68Ga\]CBP8 to detect collagen deposition in early interstitial lung disease.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/06/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Interstitial Lung Disease
Register for Updates
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
NCT05892614
Recruiting
This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: aTyr Investigative Site, Los Angeles, California +14 locations
Conditions: Interstitial Lung Disease
Register for Updates
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
NCT03478826
Recruiting
To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Interstitial Lung Disease
Register for Updates